03/21/23 10:00 AMNYSE : PFE conferencesPfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with AnalystsPfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2023. About Pfizer: Breakthroughs That Change Patients’ Lives. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.RHEA-AIneutral
03/16/23 7:30 PMOTC, NYSE : ALPMY, PFE clinical trialPhase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate CancerPfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from theRHEA-AIvery positive
03/16/23 7:30 PMNYSE, OTC : PFE, ALPMY clinical trialPhase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate CancerPfizer Inc. and Astellas Pharma Inc. today announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI ® in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical...RHEA-AIvery positive
03/16/23 3:18 PMNYSE : PFE FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™Pfizer Inc. announced today that the U.S. Food and Drug Administration’ s Antimicrobial Drugs Advisory Committee voted 16 to 1 that available data support the safety and effectiveness of PAXLOVID™ for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to severe illness. “We believe it is critical for adults who...RHEA-AIneutral
03/13/23 7:30 PMOTC, NYSE : ALPMY, PFE clinical trialAstellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint"With the rising incidence of prostate cancer diagnoses among men in China, there is a need for new and effective treatment options," said Ahsan Arozullah, M.D., M.P.H., Senior Vice President and Head of Development Therapeutic Areas, Astellas. "As observed in our global Phase 3 ARCHES study, and now reaffirmed with China ARCHES, XTANDI significantly delays the time to...RHEA-AIneutral
03/13/23 6:45 AMNasdaq, NYSE : SGEN, PFE Pfizer Invests $43 Billion to Battle CancerPfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion Proposed combination enhances Pfizer’ s position as a leading company in Oncology Seagen’ s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates strongly complement Pfizer’ s Oncology portfolio...RHEA-AIpositive
03/13/23 6:45 AMNYSE, Nasdaq : PFE, SGEN Pfizer Invests $43 Billion to Battle CancerPfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion Proposed combination enhances Pfizer’ s position as a leading company in Oncology Seagen’ s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates strongly complement Pfizer’ s Oncology portfolio...RHEA-AIpositive
03/10/23 6:45 AMNYSE : PFE fda approvalPfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA ApprovalPfizer Inc. today announced the U.S. Food and Drug Administration has approved ZAVZPRET™, the first and only calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults. “The FDA approval of ZAVZPRET marks a significant breakthrough for people with migraine who need freedom from pain and...RHEA-AIvery positive
02/28/23 4:40 PMNYSE : PFE Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older AdultsPfizer Inc. announced today that the U.S. Food and Drug Administration’ s Vaccines and Related Biological Products Advisory Committee voted that available data is adequate to support the safety and effectiveness of its respiratory syncytial virus bivalent vaccine candidate PF-06928316 or RSVpreF. “In older adults, RSV can result in serious illness,...RHEA-AIneutral
02/27/23 10:00 AMNYSE : PFE conferencesPfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ConferencePfizer Inc. invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceutical Business; Rodrigo Puga, U.S. Commercial and Global Business Lead for Internal Medicine; and Annaliesa Anderson, Senior Vice President and Chief Scientific Officer, Vaccine...RHEA-AIneutral
